Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Cash from Investing Activities (2016 - 2021)

BioCorRx's Cash from Investing Activities history spans 10 years, with the latest figure at -$11995.0 for Q4 2021.

  • For Q4 2021, Cash from Investing Activities fell 324.3% year-over-year to -$11995.0; the TTM value through Sep 2022 reached -$11995.0, up 70.62%, while the annual FY2021 figure was -$49997.0, 441.86% down from the prior year.
  • Cash from Investing Activities for Q4 2021 was -$11995.0 at BioCorRx, up from -$35985.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $801.0 in Q3 2019 and bottomed at -$54968.0 in Q4 2019.
  • The 4-year median for Cash from Investing Activities is -$11995.0 (2021), against an average of -$18854.6.
  • The largest annual shift saw Cash from Investing Activities surged 500.5% in 2019 before it crashed 899.0% in 2020.
  • A 4-year view of Cash from Investing Activities shows it stood at -$26184.0 in 2018, then plummeted by 109.93% to -$54968.0 in 2019, then surged by 94.86% to -$2827.0 in 2020, then tumbled by 324.3% to -$11995.0 in 2021.
  • Per Business Quant, the three most recent readings for BICX's Cash from Investing Activities are -$11995.0 (Q4 2021), -$35985.0 (Q3 2021), and -$2017.0 (Q1 2021).